Massachusetts is currently home to 3148 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Improving Social Relationships for Adolescents with Central Disorders of Hypersomnolence
NCT06251063
Recruiting
The goal of this study is to test a web-based psychoeducational resource for adolescents with central disorders of hypersomnolence and their families. The investigators hope to assess the website's usability, acceptability, and feasibility, as well as its potential effect on social relationship health. Participants will be asked to review the content of the psychoeducational websites. The participants will then provide feedback on the website, as well as the adolescent's social relationships an... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
02/16/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Register for Updates
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults with Social Anxiety Disorder (PALISADE-3)
NCT06358651
Recruiting
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/14/2025
Locations: Vistagen Clinical Site, Boston, Massachusetts
Conditions: Social Anxiety Disorder
Register for Updates
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
NCT06316297
Recruiting
The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to three dose levels in adult participants aged 18 to 45 years with moderate to severe acne.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
02/14/2025
Locations: Metro Boston Clinical Partners Site Number : 8400008, Brighton, Massachusetts
Conditions: Acne
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688
Recruiting
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: UMass Memorial Medical Center - University Campus, Worcester, Massachusetts
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Study of Ribociclib and Everolimus in HGG and DIPG
NCT05843253
Recruiting
The goal of this study is to determine the efficacy of the study drugs ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target. The main question the study aims to answer is whether the combination of ribociclib and everolimus can prolong the life of patients diagnosed with HGG, including DIPG.
Gender:
ALL
Ages:
Between 12 months and 39 years
Trial Updated:
02/14/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
Register for Updates
Study of Oral MRT-2359 in Selected Cancer Patients
NCT05546268
Recruiting
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site, diffuse large B-cell lymphoma (DLBCL), and tumors with L-MYC or N-MYC amplification. Patients receive escalating doses of a GSPT1 molecular glue degrader MRT-2359 to determine safety, tolerability, maximum tolerated dose (MTD) and/or recommended Phase... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: NSCLC, SCLC, DLBCL, NSCLC With High or Low L-MYC or N-MYC Expression, High Grade Neuroendocrine Cancer, L-MYC and N-MYC Amplified Solid Tumors, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
Register for Updates
Pragmatic Trial of Remote TDCS and Somatosensory Training for Phantom Limb Pain with Machine Learning to Predict Treatment Response
NCT05188183
Recruiting
The investigators have designed a pragmatic trial of home-based transcranial direct current stimulation (tDCS) for phantom limb pain (PLP), the PLP-EVEREST trial (PLP-EffectiVEness pRagmatic Stimulation Trial) to test a portable device that would reach underrepresented populations and would validate this therapy in a more pragmatic setting. Subjects will be randomized to home-based tDCS of the primary motor cortex (M1) with somatosensory training or usual care only (including their current pharm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Spaulding Hospital Cambridge, Cambridge, Massachusetts
Conditions: Phantom Limb Pain
Register for Updates
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma with NTRK Fusion
NCT04655404
Recruiting
This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given. The study will also evaluate the safety of larotrectinib when given with chemotherapy in your children; as well as the safety larotrectinib when given post-focal radiation therapy.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
02/14/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Register for Updates
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
NCT02486562
Recruiting
iConquerMS™ is a research initiative developed by and for people with multiple sclerosis (MS) to contribute their health data and ideas to advance and accelerate research into MS. iConquerMS welcomes adults with MS and others interested in advancing MS research, children and teens with MS and their family members (via iConquerMS Kids \& Teens) and MS caregivers (via iConquerMS Caregivers) to participate.
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: Accelerated Cure Project, Waltham, Massachusetts
Conditions: Multiple Sclerosis
Register for Updates
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038
Recruiting
The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Research Site, Boston, Massachusetts
Conditions: Chronic Lymphocytic Leukaemia, Small Lymphocytic Leukaemia, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma
Register for Updates
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
NCT06465953
Recruiting
This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previously. Participants will be randomized to receive either ivosidenib (IVO) alone or azacitidine (AZA) alone. IVO will be administered daily throughout the 28-day treatment cycle and AZA will be administered for the first 7 days of each 28-day cycle. Study visits will be conducted every week during Cy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
Register for Updates
A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms
NCT06034002
Recruiting
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered in participants with myeloproliferative neoplasms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Myeloproliferative Neoplasms
Register for Updates